396
Participants
Start Date
May 1, 2022
Primary Completion Date
December 1, 2027
Study Completion Date
December 1, 2032
Photon Radiotherapy
nCXT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
Proton Radiotherapy
nCPT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
RECRUITING
Aarhus University Hospital (AUH), Aarhus
RECRUITING
University Hospital Zurich (USZ), Zurich
RECRUITING
Catholic University of Leuven, Leuven
NOT_YET_RECRUITING
Centre Léon Bérard (CLB), Lyon
NOT_YET_RECRUITING
Centre Antoine Lacassagne (CAL), Nice
NOT_YET_RECRUITING
Institut Curie, Paris
RECRUITING
Technische Universität Dresden (TUD), Dresden
RECRUITING
San Raffaele Hospital, Milan
RECRUITING
Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia
RECRUITING
Azienda Provinciale Per I Servizi Sanitari (APSS), Trento
WITHDRAWN
Academisch Ziekenhuis Groningen (UMCG), Groningen
WITHDRAWN
Stichting Maastricht Radiation Oncology (MAASTRO), Maastricht
RECRUITING
Paul Scherrer Institute (PSI), Villigen
WITHDRAWN
University College London Hospital (UCLH), London
NOT_YET_RECRUITING
The Christie NHS foundation trust, Manchester
Collaborators (1)
University of Leeds
OTHER
KU Leuven
OTHER
University College, London
OTHER
Aarhus University Hospital
OTHER
Technische Universität Dresden
OTHER
Academisch Ziekenhuis Groningen
OTHER
CNAO National Center of Oncological Hadrontherapy
OTHER
Agenzia Nazionale per i Servizi Sanitari Regionali
OTHER
Centre Antoine Lacassagne
OTHER
Centre Leon Berard
OTHER
Institut Curie
OTHER
Maastro Clinic, The Netherlands
OTHER
University College London Hospitals
OTHER
The Christie NHS Foundation Trust
OTHER
Paul Scherrer Institut, Center for Proton Therapy
OTHER
HollandPTC
INDUSTRY
IBA worldwide
UNKNOWN
Varian- A Siemens Healthineer Company
UNKNOWN
University of Aarhus
OTHER